Overview

Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease

Status:
Terminated
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
Phase:
Phase 2
Details
Lead Sponsor:
Affymax
Treatments:
Hematinics